1
|
Kolwicz SC, Hall JK, Moussavi-Harami F, Chen X, Hauschka SD, Chamberlain JS, Regnier M, Odom GL. Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate. JACC Basic Transl Sci 2019; 4:778-791. [PMID: 31998848 PMCID: PMC6978556 DOI: 10.1016/j.jacbts.2019.06.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 06/20/2019] [Accepted: 06/20/2019] [Indexed: 01/13/2023]
Abstract
Mutations in the gene encoding for dystrophin leads to structural and functional deterioration of cardiomyocytes and is a hallmark of cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. Administration of recombinant adeno-associated viral vectors delivering microdystrophin or ribonucleotide reductase (RNR), under muscle-specific regulatory control, rescues both baseline and high workload-challenged hearts in an aged, DMD mouse model. However, only RNR treatments improved both systolic and diastolic function under those conditions. Cardiac-specific recombinant adeno-associated viral treatment of RNR holds therapeutic promise for improvement of cardiomyopathy in DMD patients.
Collapse
Key Words
- CK8, miniaturized murine creatine kinase regulatory cassette
- CMV, cytomegalovirus
- DMD, Duchenne muscular dystrophy
- RNR, ribonucleotide reductase
- cTnT, cardiac troponin T
- cardiomyopathy
- dADP, deoxy-adenosine diphosphate
- dATP, deoxy-adenosine triphosphate
- diastolic dysfunction
- dystrophin
- mdx, mouse muscular dystrophy model
- rAAV, recombinant adeno-associated viral vector
- recombinant adeno-associated virus vectors
- ribonucleotide reductase
- μDys, microdystrophin
Collapse
Affiliation(s)
- Stephen C. Kolwicz
- Mitochondria and Metabolism Center, University of Washington, Seattle, Washington
| | - John K. Hall
- Department of Neurology, University of Washington, Seattle, Washington
| | - Farid Moussavi-Harami
- Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington
| | - Xiolan Chen
- Department of Biochemistry, University of Washington, Seattle, Washington
- Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington
| | - Stephen D. Hauschka
- Department of Biochemistry, University of Washington, Seattle, Washington
- Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington
| | - Jeffrey S. Chamberlain
- Department of Neurology, University of Washington, Seattle, Washington
- Department of Biochemistry, University of Washington, Seattle, Washington
- Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington
| | - Michael Regnier
- Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington
- Department of Bioengineering, University of Washington, Seattle, Washington
- Center for Cardiovascular Biology, University of Washington, Seattle, Washington
| | - Guy L. Odom
- Department of Neurology, University of Washington, Seattle, Washington
- Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington
- Center for Cardiovascular Biology, University of Washington, Seattle, Washington
| |
Collapse
|